Key result
Late-phase artesunate slows HF progression in mice by mitigating myocardial inflammation, fibrosis, and ferroptosis.
Why the study?
Heart failure poses a major global challenge due to high morbidity and mortality, prompting investigation into the therapeutic potential of artesunate in an isoprenaline-induced mouse model.
Does artesunate improve cardiac function and reduce fibrosis in a mouse model of isoprenaline-induced heart failure?
Does artesunate improve cardiac function and reduce fibrosis in a mouse model of isoprenaline-induced heart failure?
Late-phase intervention with artesunate slows heart failure progression in mice by mitigating myocardial inflammation, fibrosis, and ferroptosis, independent of hypertrophy regression.
Answers are grounded in this paper and cite their sources.
May support further preclinical study of artesunate in heart failure; hypothesis-generating and should not change practice.
Heart failure (HF) poses a substantial challenge to healthcare systems globally, particularly at the advanced stages of various cardiac diseases, due to its high morbidity and mortality rates. This study aimed to assess the therapeutic potential of artesunate in a mouse model of HF induced by isoprenaline. Adult male C57BL/6J mice were subcutaneously injected with isoprenaline (50 mg/kg/day) for 14 consecutive days, with artesunate administered during the last 7 days. Strikingly, late-phase intervention with artesunate retarded the decline of cardiac function and attenuated lung congestion in HF mice. Although it did not ameliorate cardiac hypertrophy, as indicated by unchanged heart weight and myocyte cross-sectional area, artesunate markedly alleviated interstitial fibrosis and downregulated mRNA expression of Tgfb1 and Col1a1 in failing hearts. Mechanistically, artesunate suppressed myocardial infiltration of monocytes/macrophages and downregulated key inflammatory genes, including Ccl2, Il6, Nos2, Il1b, and Tnf. Furthermore, it elevated protein levels of Nrf2, glutathione peroxidase 4, and heme oxygenase-1, and suppressed ferroptosis in failing hearts. In summary, late-phase intervention with artesunate slows HF progression in mice by mitigating myocardial inflammation, fibrosis, and ferroptosis, independent of hypertrophy regression. SIGNIFICANCE STATEMENT: Although late-phase intervention with artesunate does not impact cardiac hypertrophy, it reduces myocardial inflammation and fibrosis, slowing heart failure progression. Our findings provide compelling evidence for artesunate as a promising therapeutic candidate, with its efficacy in a clinically relevant experimental context underscoring its significant translational potential.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Heart failure. Artesunate was evaluated on Cardiac function and hypertrophy. Late-phase intervention with artesunate slowed heart failure progression in mice by mitigating myocardial inflammation, fibrosis, and ferroptosis, independent of hypertrophy regression.
Synapse has enriched 10 related papers. Consider them for comparative context: